Lowers the risk of hospitalization for heart failure. ANDA 211478, held by Msn. Dapagliflozin.
As of Nov 15, 2026, ANDA 211478 (Dapagliflozin), held by Msn, was first approved by FDA on Apr 6, 2026, with 0 approved supplements and 0 published complete response letters.
Dapagliflozin tablet is indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Dapagliflozin tablet is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. Dapagliflozin tablet is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 6, 2026 | Original application | Approved |
| Dapagliflozin5MG · tablet;oral | Dapagliflozin | Rx |
| Dapagliflozin10MG · tablet;oral | Dapagliflozin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters